395 related articles for article (PubMed ID: 12097261)
1. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.
Adam BL; Qu Y; Davis JW; Ward MD; Clements MA; Cazares LH; Semmes OJ; Schellhammer PF; Yasui Y; Feng Z; Wright GL
Cancer Res; 2002 Jul; 62(13):3609-14. PubMed ID: 12097261
[TBL] [Abstract][Full Text] [Related]
2. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients.
Qu Y; Adam BL; Yasui Y; Ward MD; Cazares LH; Schellhammer PF; Feng Z; Semmes OJ; Wright GL
Clin Chem; 2002 Oct; 48(10):1835-43. PubMed ID: 12324514
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic potential of serum proteomic patterns in prostate cancer.
Bañez LL; Prasanna P; Sun L; Ali A; Zou Z; Adam BL; McLeod DG; Moul JW; Srivastava S
J Urol; 2003 Aug; 170(2 Pt 1):442-6. PubMed ID: 12853795
[TBL] [Abstract][Full Text] [Related]
4. Application of surface-enhanced laser desorption/ionization time-of-flight-based serum proteomic array technique for the early diagnosis of prostate cancer.
Pan YZ; Xiao XY; Zhao D; Zhang L; Ji GY; Li Y; Yang BX; He DC; Zhao XJ
Asian J Androl; 2006 Jan; 8(1):45-51. PubMed ID: 16372118
[TBL] [Abstract][Full Text] [Related]
5. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
[TBL] [Abstract][Full Text] [Related]
6. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
[TBL] [Abstract][Full Text] [Related]
7. [Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry].
Pan YZ; Xiao XY; Zhao D; Zhang L; Ji GY; Li Y; He DC; Zhao XJ; Yang BX
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3172-5. PubMed ID: 16405834
[TBL] [Abstract][Full Text] [Related]
8. Correspondence re: B-L. Adam et al., Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res., 62: 3609-3614, 2002.
Stattin P; Hakama M
Cancer Res; 2003 May; 63(10):2701; author reply 2701-2. PubMed ID: 12750300
[No Abstract] [Full Text] [Related]
9. [Tree analysis pattern of mass spectral urine profiles in differential diagnosis of bladder transitional cell carcinoma].
Wu DL; Zhang YF; Guan M; Liu WW; Xu YM; Jin SB; Zhang J; Jin CR; Lü Y
Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):274-7. PubMed ID: 17760254
[TBL] [Abstract][Full Text] [Related]
10. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient.
Zhang YF; Wu DL; Guan M; Liu WW; Wu Z; Chen YM; Zhang WZ; Lu Y
Clin Biochem; 2004 Sep; 37(9):772-9. PubMed ID: 15329315
[TBL] [Abstract][Full Text] [Related]
11. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry.
Cazares LH; Adam BL; Ward MD; Nasim S; Schellhammer PF; Semmes OJ; Wright GL
Clin Cancer Res; 2002 Aug; 8(8):2541-52. PubMed ID: 12171882
[TBL] [Abstract][Full Text] [Related]
12. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry serum protein profiling to identify nasopharyngeal carcinoma.
Ho DW; Yang ZF; Wong BY; Kwong DL; Sham JS; Wei WI; Yuen AP
Cancer; 2006 Jul; 107(1):99-107. PubMed ID: 16708360
[TBL] [Abstract][Full Text] [Related]
13. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
[TBL] [Abstract][Full Text] [Related]
14. Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
Liu J; Zheng S; Yu JK; Zhang JM; Chen Z
J Zhejiang Univ Sci B; 2005 Jan; 6(1):4-10. PubMed ID: 15593384
[TBL] [Abstract][Full Text] [Related]
15. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
16. Classification analyses for prostate cancer, benign prostate hyperplasia and healthy subjects by SERS-based immunoassay of multiple tumour markers.
Zhou L; Liu Y; Wang F; Jia Z; Zhou J; Jiang T; Petti L; Chen Y; Xiong Q; Wang X
Talanta; 2018 Oct; 188():238-244. PubMed ID: 30029370
[TBL] [Abstract][Full Text] [Related]
17. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia.
Giskeødegård GF; Hansen AF; Bertilsson H; Gonzalez SV; Kristiansen KA; Bruheim P; Mjøs SA; Angelsen A; Bathen TF; Tessem MB
Br J Cancer; 2015 Dec; 113(12):1712-9. PubMed ID: 26633561
[TBL] [Abstract][Full Text] [Related]
18. Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.
Al-Ruwaili JA; Larkin SE; Zeidan BA; Taylor MG; Adra CN; Aukim-Hastie CL; Townsend PA
Cancer Genomics Proteomics; 2010; 7(2):93-103. PubMed ID: 20335524
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses.
Jayapalan JJ; Ng KL; Razack AH; Hashim OH
Electrophoresis; 2012 Jul; 33(12):1855-62. PubMed ID: 22740474
[TBL] [Abstract][Full Text] [Related]
20. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
